These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21454217)

  • 21. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.
    Landau H; Hassoun H; Bello C; Hoover E; Riedel ER; Nimer SD; Comenzo RL
    Amyloid; 2011 Jun; 18 Suppl 1():135-6. PubMed ID: 21838462
    [No Abstract]   [Full Text] [Related]  

  • 23. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
    Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
    J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
    J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
    Venner CP; Lane T; Foard D; Rannigan L; Gibbs SD; Pinney JH; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Blood; 2012 May; 119(19):4387-90. PubMed ID: 22331187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute dyspnea from treatment of AL amyloidisis with bortezomib.
    Ghose A; Tariq Z; Taj A; Chaudhary R
    Am J Ther; 2011 Jul; 18(4):e123-5. PubMed ID: 20335791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
    Jagannath S; Durie BG; Wolf J; Camacho E; Irwin D; Lutzky J; McKinley M; Gabayan E; Mazumder A; Schenkein D; Crowley J
    Br J Haematol; 2005 Jun; 129(6):776-83. PubMed ID: 15953004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma.
    Nabhan C; Villines D; Dalal N; Tolzien K; Kozolff M; Starr A
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):26-31. PubMed ID: 21752745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
    Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
    Reece DE; Hegenbart U; Sanchorawala V; Merlini G; Palladini G; Bladé J; Fermand JP; Hassoun H; Heffner L; Vescio RA; Liu K; Enny C; Esseltine DL; van de Velde H; Cakana A; Comenzo RL
    Blood; 2011 Jul; 118(4):865-73. PubMed ID: 21562045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous macroglobulinosis treated with bortezomib and rituximab.
    Marchand T; Tas P; Houot R; Dauriac C; Lamy T; Cahu X
    Eur J Haematol; 2011 Jul; 87(1):98. PubMed ID: 21418108
    [No Abstract]   [Full Text] [Related]  

  • 34. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
    Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
    Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
    Jaccard A; Comenzo RL; Hari P; Hawkins PN; Roussel M; Morel P; Macro M; Pellegrin JL; Lazaro E; Mohty D; Mercie P; Decaux O; Gillmore J; Lavergne D; Bridoux F; Wechalekar AD; Venner CP
    Haematologica; 2014 Sep; 99(9):1479-85. PubMed ID: 24859879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
    Chari A; Barley K; Jagannath S; Osman K
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):55-61. PubMed ID: 23098888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.
    Terrier B; Jaccard A; Harousseau JL; Delarue R; Tournilhac O; Hunault-Berger M; Hamidou M; Dantal J; Bernard M; Grosbois B; Morel P; Coiteux V; Gisserot O; Rodon P; Hot A; Elie C; Leblond V; Fermand JP; Fakhouri F
    Medicine (Baltimore); 2008 Mar; 87(2):99-109. PubMed ID: 18344807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib in systemic AL amyloidosis: a single center experience.
    Coriu D; Badelita S; Talmaci R; Dobrea C; Dogaru M; Ostroveanu D; Crisan M
    Amyloid; 2011 Jun; 18 Suppl 1():148-50. PubMed ID: 21838467
    [No Abstract]   [Full Text] [Related]  

  • 39. Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience.
    Abonour R; Kramer G; Suvannasankha A; Benson MD
    Amyloid; 2011 Jun; 18 Suppl 1():151. PubMed ID: 21838468
    [No Abstract]   [Full Text] [Related]  

  • 40. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.